Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
ATHEROSCLEROSIS / BASIC RESEARCH
Abnormal TPM2 expression is involved in regulation of atherosclerosis progression via mediating RhoA signaling in vitro
1
Department of Material Supply, Yantai Yuhuangding Hospital, Yantai 264000, Shandong, China
2
Department of Material Purchasing, Yantai Yeda Hospital, China
3
Department of Cardiology Second Ward, Shandong Weihai Central Hospital, Weihai 264400, Shandong, China
4
Department of Cardiovascular Medicine, Weihai Municipal Hospital, Weihai 264400, Shandong, China
5
Department of Cardiology, Yantai Yuhuangding Hospital, Yantai 264000, Shandong, China
Submission date: 2021-05-19
Final revision date: 2021-06-08
Acceptance date: 2021-06-21
Online publication date: 2021-07-03
Publication date: 2024-08-04
Arch Med Sci 2024;20(4):1197-1208
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Ox-LDL (oxidized low-density lipoprotein)-induced endothelial cell injury and dysfunction of vascular smooth muscle cells play critical roles in the development of atherosclerosis (AS). Tropomyosin 2 (TPM2) has been implicated in cardiac diseases, but its critical role and regulatory mechanism in AS progression have not yet been elucidated.
Material and methods:
The expression of TPM2 was investigated in AS tissues. Ox-LDL was used to construct an AS in vitro model based on endothelial and vascular smooth muscle cells (HAECs and VSMCs). An overexpression assay was performed to evaluate the role of TPM2 in AS. Meanwhile, the involvement of the RhoA pathway in TPM2-mediated AS progression was evaluated using narciclasine.
Results:
Tropomyosin 2 was dramatically upregulated in both AS tissues and ox-LDL-induced HAECs. Overexpression of TPM2 attenuated ox-LDL-stimulated cell growth depression, inflammatory and adhesive responses in HAECs, as well as oxidative stress and mitochondrial dysfunction. Additionally, VSMCs, impacted by TPM2-overexpressed HAECs, showed alleviated cellular processes which were abnormally activated by ox-LDL. Furthermore, depressed activation of the RhoA pathway was found in TPM2-overexpressed HAECs and activating the signaling rescued these effects of TPM2 exerted on ox-LDL-stimulated HAECs and VSMCs.
Conclusions:
TPM2 had an advantageous impact on ox-LDL-induced AS progression in vitro by mediating the RhoA pathway. This evidence might contribute to the therapy of AS.
Ox-LDL (oxidized low-density lipoprotein)-induced endothelial cell injury and dysfunction of vascular smooth muscle cells play critical roles in the development of atherosclerosis (AS). Tropomyosin 2 (TPM2) has been implicated in cardiac diseases, but its critical role and regulatory mechanism in AS progression have not yet been elucidated.
Material and methods:
The expression of TPM2 was investigated in AS tissues. Ox-LDL was used to construct an AS in vitro model based on endothelial and vascular smooth muscle cells (HAECs and VSMCs). An overexpression assay was performed to evaluate the role of TPM2 in AS. Meanwhile, the involvement of the RhoA pathway in TPM2-mediated AS progression was evaluated using narciclasine.
Results:
Tropomyosin 2 was dramatically upregulated in both AS tissues and ox-LDL-induced HAECs. Overexpression of TPM2 attenuated ox-LDL-stimulated cell growth depression, inflammatory and adhesive responses in HAECs, as well as oxidative stress and mitochondrial dysfunction. Additionally, VSMCs, impacted by TPM2-overexpressed HAECs, showed alleviated cellular processes which were abnormally activated by ox-LDL. Furthermore, depressed activation of the RhoA pathway was found in TPM2-overexpressed HAECs and activating the signaling rescued these effects of TPM2 exerted on ox-LDL-stimulated HAECs and VSMCs.
Conclusions:
TPM2 had an advantageous impact on ox-LDL-induced AS progression in vitro by mediating the RhoA pathway. This evidence might contribute to the therapy of AS.
REFERENCES (39)
1.
Dai X, Zhang N, Cheng Y, et al. RNA-binding protein trinucleotide repeat-containing 6A regulates the formation of circular RNA circ0006916, with important functions in lung cancer cells. Carcinogenesis 2018; 39: 981-92.
2.
Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-22.
3.
Santoro MM, Samuel T, Mitchell T, et al. Birc2 (cIap1) regulates endothelial cell integrity and blood vessel homeostasis. Nat Genet 2007; 39: 1397-402.
4.
Mano T, Masuyama T, Yamamoto K, et al. Endothelial dysfunction in the early stage of atherosclerosis precedes appearance of intimal lesions assessable with intravascular ultrasound. Am Heart J 1996; 131: 231-8.
5.
Gorenne I, Kumar S, Gray K, et al. Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis. Circulation 2013; 127: 386-96.
6.
Sato K, Yamashita T, Shirai R, et al. Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. Int J Mol Sci 2018; 19: 1293.
7.
Zhou Z, Subramanian P, Sevilmis G, et al. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing cxcl1 from the endothelium. Cell Metab 2011; 13: 592-600.
8.
Ishigaki Y, Katagiri H, Gao J, et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 2008; 118: 75-83.
9.
Galle J, Hansenhagge T, Wanner C, et al. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 2006; 185: 219-26.
10.
Karpicheva OE, Simonyan AO, Kuleva NV, Redwood CS, Borovikov YS. Myopathy-causing Q147P TPM2 mutation shifts tropomyosin strands further towards the open position and increases the proportion of strong-binding cross-bridges during the ATPase cycle. Biochim Biophys Acta 2016; 1864: 260-7.
11.
Brayford S, Bryce NS, Schevzov G, et al. Tropomyosin promotes lamellipodial persistence by collaborating with Arp2/3 at the leading edge. Curr Biol 2016; 26: 1312-8.
12.
Gao R, Yu Y, Inoue A, Widodo N, Kaul SC, Wadhwa R. Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) promotes tumor metastasis by induction of genes involved in extracellular matrix, cell movement, and angiogenesis. J Biol Chem 2013; 288: 15046-56.
13.
Kubo E, Hasanova N, Fatma N, Sasaki H, Singh DP. Elevated tropomyosin expression is associated with epithelial-mesenchymal transition of lens epithelial cells. J Cell Mol Med 2013; 17: 212-21.
14.
Meng LB, Shan MJ, Qiu Y, et al. TPM2 as a potential predictive biomarker for atherosclerosis. Aging (Albany NY) 2019; 11: 6960-82.
15.
Tirosh O, Sen CK, Roy S, Packer L. Cellular and mitochondrial changes in glutamate-induced HT4 neuronal cell death. Neuroscience 2000; 97: 531-41.
16.
Song N, Jia L, Cao H, et al. Gypenoside inhibits endothelial cell apoptosis in atherosclerosis by modulating mitochondria through PI3K/Akt/Bad pathway. Biomed Res Int 2020; 2020: 2819658.
17.
Cui C, Wang X, Shang XM, et al. lncRNA 430945 promotes the proliferation and migration of vascular smooth muscle cells via the ROR2/RhoA signaling pathway in atherosclerosis. Mol Med Rep 2019; 19: 4663-72.
18.
Schober A, Nazari-Jahantigh M, Wei Y, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 2014; 20: 368-76.
19.
Li F, Lin D, Gao L. LncRNA TUG1 promotes proliferation of vascular smooth muscle cell and atherosclerosis through regulating miRNA-21/PTEN axis. Eur Rev Med Pharmacol Sci 2018; 22: 7439-47.
20.
Paone S, Baxter AA, Hulett MD, Poon IKH. Endothelial cell apoptosis and the role of endothelial cell-derived extracellular vesicles in the progression of atherosclerosis. Cell Mol Life Sci 2019; 76: 1093-106.
21.
Sun HJ, Wu ZY, Nie XW, Bian JS. Role of endothelial dysfunction in cardiovascular diseases: the link between inflammation and hydrogen sulfide. Front Pharmacol 2019; 10: 1568.
22.
Geng J, Xu H, Yu X, et al. Rosuvastatin protects against oxidized lowdensity lipoproteininduced endothelial cell injury of atherosclerosis in vitro. Mol Med Rep 2019; 19: 432-40.
23.
Peng W, Cai G, Xia Y, et al. Mitochondrial dysfunction in atherosclerosis. DNA Cell Biol 2019; 38: 597-606.
24.
Zhang C, Chen D, Maguire EM, et al. Cbx3 inhibits vascular smooth muscle cell proliferation, migration, and neointima formation. Cardiovasc Res 2018; 114: 443-55.
25.
Feng S, Gao L, Zhang D, et al. MiR-93 regulates vascular smooth muscle cell proliferation, and neointimal formation through targeting Mfn2. Int J Biol Sci 2019; 15: 2615-26.
26.
He L, Zhou Q, Huang Z, et al. PINK1/Parkin-mediated mitophagy promotes apelin-13-induced vascular smooth muscle cell proliferation by AMPKalpha and exacerbates atherosclerotic lesions. J Cell Physiol 2019; 234: 8668-82.
27.
Lin X, Li S, Wang YJ, et al. Exosomal Notch3 from high glucose-stimulated endothelial cells regulates vascular smooth muscle cells calcification/aging. Life Sci 2019; 232: 116582.
28.
Dai Z, Zhu MM, Peng Y, et al. Endothelial and smooth muscle cell interaction via FoxM1 signaling mediates vascular remodeling and pulmonary hypertension. Am J Respir Crit Care Med 2018; 198: 788-802.
29.
Zheng B, Yin WN, Suzuki T, et al. Exosome-mediated miR-155 transfer from smooth muscle cells to endothelial cells induces endothelial injury and promotes atherosclerosis. Mol Ther 2017; 25: 1279-94.
30.
Ma Y, Xiao T, Xu Q, Shao X, Wang H. iTRAQ-based quantitative analysis of cancer-derived secretory proteome reveals TPM2 as a potential diagnostic biomarker of colorectal cancer. Front Med 2016; 10: 278-85.
31.
Zhang J, Zhang J, Xu S, et al. Hypoxia-induced TPM2 methylation is associated with chemoresistance and poor prognosis in breast cancer. Cell Physiol Biochem 2018; 45: 692-705.
32.
Davidson AE, Siddiqui FM, Lopez MA, et al. Novel deletion of lysine 7 expands the clinical, histopathological and genetic spectrum of TPM2-related myopathies. Brain 2013; 136: 508-21.
33.
Mokbel N, Ilkovski B, Kreissl M, et al. K7del is a common TPM2 gene mutation associated with nemaline myopathy and raised myofibre calcium sensitivity. Brain 2013; 136 (Pt 2): 494-507.
34.
Lornage Xr. Identification and functional characterization of novel genes implicated in congenital myopathies. Université de Strasbourg, 2019.
35.
Bailey JJ, Schirrmacher R, Farrell K, et al. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – part II. Expert Opin Ther Pat 2017; 27: 831-49.
36.
Bartelt A, John C, Schaltenberg N, et al. Thermogenic adipocytes promote HDL turnover and reverse cholesterol transport. Nat Commun 2017; 8: 15010.
37.
Cui J, Cai Y, Hu Y, et al. Epigenetic silencing of TPM2 contributes to colorectal cancer progression upon RhoA activation. Tumour Biol 2016; 37: 12477-83.
38.
Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci 2011; 32: 167-73.
39.
Li N, Chen J, Zhao J, Wang T. MicroRNA-3188 targets ETS-domain protein 4 and participates in RhoA/ROCK pathway to regulate the development of atherosclerosis. Pharmazie 2017; 72: 687-93.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
